NZ719049A - Cancer treatment with combination of plinabulin and taxane - Google Patents
Cancer treatment with combination of plinabulin and taxaneInfo
- Publication number
- NZ719049A NZ719049A NZ719049A NZ71904913A NZ719049A NZ 719049 A NZ719049 A NZ 719049A NZ 719049 A NZ719049 A NZ 719049A NZ 71904913 A NZ71904913 A NZ 71904913A NZ 719049 A NZ719049 A NZ 719049A
- Authority
- NZ
- New Zealand
- Prior art keywords
- combination
- plinabulin
- taxane compound
- taxane
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ719049A true NZ719049A (en) | 2020-06-26 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ719049A NZ719049A (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (OSRAM) |
| EP (1) | EP3076972B1 (OSRAM) |
| JP (1) | JP6411523B2 (OSRAM) |
| KR (1) | KR102225371B1 (OSRAM) |
| CN (1) | CN105705148B (OSRAM) |
| AU (1) | AU2013402794B2 (OSRAM) |
| BR (1) | BR112016007946A2 (OSRAM) |
| CA (1) | CA2926771C (OSRAM) |
| DK (1) | DK3076972T3 (OSRAM) |
| ES (1) | ES2902665T3 (OSRAM) |
| IL (1) | IL244984B (OSRAM) |
| MX (1) | MX384751B (OSRAM) |
| MY (1) | MY185650A (OSRAM) |
| NZ (1) | NZ719049A (OSRAM) |
| RU (1) | RU2662298C2 (OSRAM) |
| SG (1) | SG11201602637QA (OSRAM) |
| WO (1) | WO2015051543A1 (OSRAM) |
| ZA (1) | ZA201602380B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201706281YA (en) * | 2015-02-12 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| CN107530340B (zh) | 2015-03-06 | 2021-06-08 | 大连万春布林医药有限公司 | 治疗脑肿瘤的方法 |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| JP7025416B2 (ja) * | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MX2019009020A (es) * | 2017-02-01 | 2019-11-12 | Beyondspring Pharmaceuticals Inc | Metodo para reducir la neutropenia. |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| JP7350015B2 (ja) * | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| BR112020015758A2 (pt) * | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| CA3119768A1 (en) * | 2018-11-14 | 2020-05-22 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| US20240299377A1 (en) * | 2019-10-15 | 2024-09-12 | Beyondspring Pharmaceuticals, Inc. | Methods and compositions for treating iron disorders |
| EP4319751A4 (en) * | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| IL166628A0 (en) | 2002-08-02 | 2006-01-15 | Nereus Pharmaceuticals Inc | Dehydrophenyl lahistins and analogs thereof and the synthesis of dehydrophenyllahistins and analogs thereof |
| KR101228104B1 (ko) * | 2004-02-04 | 2013-02-01 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의합성방법 |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| EP2968536B1 (en) | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MY185650A (en) | 2021-05-27 |
| EP3076972B1 (en) | 2021-10-06 |
| ZA201602380B (en) | 2022-05-25 |
| KR102225371B1 (ko) | 2021-03-10 |
| AU2013402794B2 (en) | 2020-02-27 |
| CA2926771C (en) | 2022-07-05 |
| EP3076972A4 (en) | 2017-12-20 |
| US10596169B2 (en) | 2020-03-24 |
| SG11201602637QA (en) | 2016-05-30 |
| BR112016007946A2 (pt) | 2017-09-12 |
| MX384751B (es) | 2025-03-14 |
| JP6411523B2 (ja) | 2018-10-24 |
| IL244984B (en) | 2022-05-01 |
| RU2016112608A (ru) | 2017-11-16 |
| DK3076972T3 (da) | 2022-01-03 |
| WO2015051543A1 (en) | 2015-04-16 |
| WO2015051543A8 (en) | 2016-04-21 |
| MX2016004441A (es) | 2016-10-28 |
| US20160250209A1 (en) | 2016-09-01 |
| EP3076972A1 (en) | 2016-10-12 |
| ES2902665T3 (es) | 2022-03-29 |
| AU2013402794A1 (en) | 2016-05-12 |
| US20200281921A1 (en) | 2020-09-10 |
| KR20160078987A (ko) | 2016-07-05 |
| CN105705148A (zh) | 2016-06-22 |
| JP2016536352A (ja) | 2016-11-24 |
| CN105705148B (zh) | 2021-03-23 |
| CA2926771A1 (en) | 2015-04-16 |
| IL244984A0 (en) | 2016-05-31 |
| RU2662298C2 (ru) | 2018-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ719049A (en) | Cancer treatment with combination of plinabulin and taxane | |
| MX2017007321A (es) | Terapias de combinacion. | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| PH12016502066A1 (en) | Methods of treating bladder cancer | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| MX377729B (es) | Métodos para tratamiento del melanoma. | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| CA2908742C (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
| ZA201708686B (en) | Nanoparticles for use as a therapeutic vaccine | |
| MX380835B (es) | Terapia de combinación pac-1. | |
| PH12016501407A1 (en) | Treatment of neoplasia | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
| PH12017500505A1 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| HK1259026A1 (zh) | 用於治疗癌症的抗趋除剂的局部递送 | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: BEYONDSPRING, INC., KY Effective date: 20160526 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2022 BY CPA GLOBAL Effective date: 20210902 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2023 BY CPA GLOBAL Effective date: 20220902 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2024 BY CPA GLOBAL Effective date: 20230831 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240829 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250904 |